Ingevity Corporation filings document formal disclosure for its specialty materials business, public-company governance, and capital structure. Form 8-K reports cover operating results, segment reporting presentation, credit agreement amendments, material agreements, and completed dispositions of North Charleston crude tall oil refinery assets and the majority of the Industrial Specialties product line.
Proxy and annual-meeting filings disclose director elections, board structure, executive compensation matters, shareholder voting results, and amendments to the company’s equity incentive plan. The filing record also includes disclosures tied to financing arrangements, continuing-operations measures, and governance matters affecting Ingevity’s common stock as a NYSE-listed issuer.
Wellington Management Group LLP and affiliated entities filed an amended Schedule 13G/A reporting beneficial ownership of 1,494,292 shares of Ingevity Corporation common stock, representing 4.24% of the class as reported. The cover lists shared voting power of 1,251,096 and shared dispositive power of 1,494,292 as of 03/31/2026. The filing states these shares are held of record by clients of Wellington investment advisers and identifies the relevant holding and adviser entities. The amendment is signed by Matthew Revell on 05/15/2026.
Ingevity Corporation reported higher first‑quarter 2026 earnings, driven by a major divestiture gain despite significant litigation charges. Net sales from continuing operations rose to $258.0 million from $247.9 million, as better pricing and mix in Performance Materials and pavement technologies offset flat volumes.
Net income from continuing operations declined to $23.4 million from $29.1 million, mainly because of a $16.2 million litigation charge tied to the BASF antitrust verdict and related costs. Including discontinued operations, total net income increased to $59.8 million, helped by a $55.6 million gain on the sale of the industrial specialties product line and crude tall oil refinery, which generated $93.1 million of cash proceeds.
Performance Materials segment EBITDA grew to $92.0 million on stronger pricing, mix and utilization, while Performance Chemicals segment EBITDA fell to $0.6 million amid weaker road markings performance. Ingevity ended the quarter with $95.4 million in cash and $1.21 billion of debt and amended its revolving credit facility, reducing commitments to $750 million and extending maturity to 2031.
Ingevity Corporation reported mixed but generally stable first quarter 2026 results. Net sales from continuing operations were $258.0 million, up 4% from a year earlier, driven mainly by pricing actions and favorable foreign exchange. Net income from continuing operations was $23.4 million, or $0.65 per diluted share, down from $29.1 million and $0.79, reflecting $22.7 million of pre-tax special charges, including a $16.2 million litigation-related reimbursement to BASF.
On a non-GAAP basis, adjusted earnings from continuing operations rose to $41.4 million, with diluted adjusted EPS of $1.15 versus $1.01, and adjusted EBITDA was $91.5 million, essentially flat with the prior year and a 35.5% margin. Performance Materials led growth, with 6% higher sales and segment EBITDA up 10%.
The company completed the sale of its North Charleston refinery assets and most Industrial Specialties products for about $93 million and divested the Road Markings product line for about $65 million. Free cash flow was negative $12.3 million, partly due to seasonal working capital, while share repurchases reached $52 million and net debt ratio was 2.6x. Ingevity reaffirmed full-year 2026 guidance, targeting net sales of $1.05–$1.15 billion, adjusted EBITDA of $370–$395 million, adjusted EPS of $4.70–$5.20, and free cash flow of $215–$245 million, excluding a $113.2 million litigation settlement payment to BASF.
PLATT PHILLIP JOHN reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp senior vice president of finance and chief accounting officer Phillip John Platt received a grant of 1,262 restricted stock units (RSUs) of common stock on May 1, 2026. This was awarded under the Ingevity Corporation 2025 Omnibus Incentive Plan and is compensation rather than a market purchase.
The RSUs will vest in three equal installments on May 1, 2027, 2028, and 2029, meaning the shares are earned over time if service conditions are met. After this award, Platt directly holds 31,633 shares of Ingevity common stock, which includes 422 shares purchased through the company’s Employee Stock Purchase Plan for the period from January 1, 2026 to March 31, 2026 at a price equal to 85% of the December 31, 2025 closing price.
Ingevity Corporation reported the results of its annual stockholder meeting held on April 29, 2026. Stockholders approved an amendment to the Ingevity Corporation 2025 Omnibus Incentive Plan, increasing the number of shares available for issuance under the plan by 580,000 shares.
All nine director nominees were elected for one-year terms. Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026. A quorum was reached, with 33,498,332 of 35,222,538 entitled shares represented.
Ingevity Corp director Luis M. Fernandez-Moreno received an equity award of 1,904 shares of common stock on April 30, 2026. The award was granted as restricted stock units under Ingevity Corporation's 2025 Omnibus Incentive Plan and carries no cash exercise price.
The restricted stock units will vest in full on April 30, 2027, meaning the director must remain eligible through that date to receive the shares outright. Following this compensation-related grant, Fernandez-Moreno directly holds 37,882 shares of Ingevity common stock as reported in this filing.
Gulyas Diane H. reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp director Diane H. Gulyas received 1,904 shares of common stock as a grant of restricted stock units. The award was granted at a price of $0.00 per share under Ingevity Corporation's 2025 Omnibus Incentive Plan and will vest in full on April 30, 2027.
Following this grant, she holds 14,788 shares of Ingevity common stock directly. Separately, 3,747 shares are held indirectly through the Diane H. Gulyas Trust, where she serves as trustee and her spouse is the beneficiary.
Ingevity Corp director Bruce D. Hoechner received a grant of 1,904 deferred stock units (DSUs) of Common Stock as equity compensation. The award was made in lieu of the annual non-employee director restricted stock unit grant and carries no cash exercise price.
The DSUs will vest on April 30, 2027 and will convert into an equal number of Ingevity Common Stock shares when his board service ends, under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. Following this grant, Hoechner directly holds 10,732 shares.
Lynch Frederick J reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp director Frederick J. Lynch reported a compensation-related equity award. He received 1,904 restricted stock units of Ingevity common stock at no purchase price under the company’s 2025 Omnibus Incentive Plan. These units will vest in full on April 30, 2027, bringing his direct holdings to 28,263 shares after the grant.
NARWOLD KAREN G reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp director receives equity award through a grant of 1,904 shares of common stock to Karen G. Narwold. The grant is reported at a price of $0.00 per share as a compensation-related award, not an open-market purchase, and increases her direct holdings to 18,900 shares.
The award represents restricted stock units granted under Ingevity Corporation's 2025 Omnibus Incentive Plan and is scheduled to vest in full on April 30, 2027. This filing records a routine equity-based compensation grant rather than a discretionary stock trade.